Literature DB >> 11115481

Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma.

K W Garey1, I Rubinstein, M H Gotfried, I J Khan, S Varma, L H Danziger.   

Abstract

Prolonged use of prednisone is associated with serious side effects, such as osteoporosis, particularly among elderly individuals. Macrolide antibiotics exhibit anti-inflammatory effects that are distinct from their antimicrobial properties. Thus, the purpose of this case report is to describe the effects of prolonged treatment with clarithromycin, 500 mg bid, in reducing prednisone requirements in three elderly patients with prednisone-dependent asthma. Three patients (one woman and two men) aged 63 to 69 years, who had been treated with 5 to 10 mg prednisone daily for at least the last 12 months, were given clarithromycin, 500 mg bid. They were followed regularly for changes in daily prednisone dose, spirometry, quality of life, and adverse events. The prednisone dose was tapered in a stepwise fashion at each clinic visit. Within 3 to 6 months of initiation of treatment with clarithromycin, and throughout the 12-month follow-up, two of three patients discontinued prednisone therapy, while the third patient displayed increased spirometry readings and noted an increasingly better quality of life. Pulmonary function tests were stable or improved over this time period, with no reported adverse events, including increased rate of infections. One patient relapsed upon discontinuation of clarithromycin therapy but has since responded to re-initiation of treatment. Long-term oral clarithromycin may have a role in reducing prednisone requirements in elderly patients with prednisone-dependent asthma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115481     DOI: 10.1378/chest.118.6.1826

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

Review 1.  Antibiotics in asthma.

Authors:  David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2004-03       Impact factor: 4.806

Review 2.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

3.  Update on infection and antibiotics in asthma.

Authors:  Donald R Rollins; David A Beuther; Richard J Martin
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

Review 4.  Pharmacotherapy of severe asthma.

Authors:  Rafael Firszt; Monica Kraft
Journal:  Curr Opin Pharmacol       Date:  2010-05-10       Impact factor: 5.547

Review 5.  Mycoplasma pneumoniae and its role in asthma.

Authors:  Nazima Nisar; Randeep Guleria; Sanjay Kumar; Tirlok Chand Chawla; Nihar Ranjan Biswas
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

6.  Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study.

Authors:  Mark H Gotfried; Rose Jung; Chad R Messick; Israel Rubinstein; Kevin W Garey; Keith A Rodvold; Larry H Danziger
Journal:  Curr Ther Res Clin Exp       Date:  2004-01

7.  A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.

Authors:  Y Kobayashi; H Wada; C Rossios; D Takagi; C Charron; P J Barnes; K Ito
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

8.  Recommendation for optimal management of severe refractory asthma.

Authors:  Jaymin B Morjaria; Riccardo Polosa
Journal:  J Asthma Allergy       Date:  2010-07-26

Review 9.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Macrolide therapy in chronic inflammatory diseases.

Authors:  Brygida Kwiatkowska; Maria Maślińska
Journal:  Mediators Inflamm       Date:  2012-08-21       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.